An ongoing TYTAN trial is a randomized, open-label, phase III study of Lapatinib in combination with Paclitaxel versus Paclitaxel alone in the second line setting of erbB2 amplified advanced GC. This evidence concerns the gene ERBB2 and gastric cancer.